Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to higher pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to higher pneumonia: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in pneumonia: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA probably leads to lower pneumonia: high‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Intervention not reported
Staff preparedness ‐ asthma knowledge NAKQ 0 to 31 scale; higher is better. 1 to 8 months · school staff
1 finding from 1 review
Intervention not reported
Health‐related quality of life (generic) SF‐36 (Physical Component Summary (PCS) score) Scale from 0‐100 Higher value post intervention is favourable, indicating improvement in health‐related quality of life · people with stable COPD
1 finding from 1 review
Intervention not reported
Health‐related quality of life (generic) SF‐36 (Mental Component Sumary (MCS) score) Scale from 0‐100 Higher value post intervention is favourable, indicating improvement in health‐related quality of life · people with stable COPD
1 finding from 1 review
Intervention not reported
Dyspnoea Basal Dyspnea Index (BDI) (score) Scale from 0‐12 Higher value post intervention is favourable, indicating improvement in dyspnoea · people with stable COPD
1 finding from 1 review
Intervention not reported
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Intervention not reported
Lung function % predicted trough FEV1 higher = better 7.6‐month · people with asthma
1 finding from 1 review
Intervention not reported
Asthma‐related quality of life (AQLQ) Scale 1 to 7; higher is better 8 months · adults or children with asthma
1 finding from 1 review